SCH-018908 - RIBAVIRIN
Total Payments
$17,750
Transactions
6
Doctors
2
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $12,000 | 3 | 1 |
| 2019 | $1,250 | 1 | 1 |
| 2018 | $2,500 | 1 | 1 |
| 2017 | $2,000 | 1 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $17,750 | 6 | 100.0% |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $17,750
Product Information
- Type Drug
- Total Payments $17,750
- Total Doctors 2
- Transactions 6
About SCH-018908 - RIBAVIRIN
SCH-018908 - RIBAVIRIN is a drug associated with $17,750 in payments to 2 healthcare providers, recorded across 6 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2020. In 2020, $12,000 was paid across 3 transactions to 1 doctors.
The most common payment nature for SCH-018908 - RIBAVIRIN is "Consulting Fee" ($17,750, 100.0% of total).